2015
DOI: 10.1371/journal.pone.0118302
|View full text |Cite
|
Sign up to set email alerts
|

Expression of CD150 in Tumors of the Central Nervous System: Identification of a Novel Isoform

Abstract: CD150 (IPO3/SLAM) belongs to the SLAM family of receptors and serves as a major entry receptor for measles virus. CD150 is expressed on normal and malignant cells of the immune system. However, little is known about its expression outside the hematopoietic system, especially tumors of the central nervous system (CNS). Although CD150 was not found in different regions of normal brain tissues, our immunohistochemical study revealed its expression in 77.6% of human CNS tumors, including glioblastoma, anaplastic a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
14
0

Year Published

2016
2016
2024
2024

Publication Types

Select...
6

Relationship

2
4

Authors

Journals

citations
Cited by 13 publications
(14 citation statements)
references
References 32 publications
0
14
0
Order By: Relevance
“…Our knowledge about CD150 expression and functions outside hematopoietic system is very limited. Protein and mRNA CD150 expression was found in > 70% tumors of CNS, including glioblastoma, astrocytoma, ependymoma and others [33]. Earlier immuhistochemical studies revealed CD150 in squamous cell carcinomas of uterine cervix, esophagus, rectum and oral cavity [26].…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations
“…Our knowledge about CD150 expression and functions outside hematopoietic system is very limited. Protein and mRNA CD150 expression was found in > 70% tumors of CNS, including glioblastoma, astrocytoma, ependymoma and others [33]. Earlier immuhistochemical studies revealed CD150 in squamous cell carcinomas of uterine cervix, esophagus, rectum and oral cavity [26].…”
Section: Discussionmentioning
confidence: 99%
“…First exon encodes leader peptide of CD150 protein, second -N-terminal variable (V) Ig-like domain, third -N-terminal constant (C2) domain, fourthtransmembrane domain and recently identified new exon (Cyt-new) followed by Cyt1-3 exons encode cytoplasmic part of CD150 ( Fig. 2A) [32,33]. As a result of alternative splicing several structurally different CD150 isoforms are generated: canonical transmembrane CD150 isoform with two immunoreceptor tyrosine-based switch motifs (ITSM) in cytoplasmic tail (mCD150), secreted isoform without transmembrane region (sCD150), novel CD150 isoform (nCD150) with alternative cytoplasmic tail, variable membrane CD150 (vmCD150) isoform, which have truncated cytoplasmic tail, and cytoplasmic CD150 (cCD150) isoform lacking leader sequence (Fig.…”
Section: Molecular Framework Of Cd150mentioning
confidence: 99%
See 2 more Smart Citations
“…Thus, CD150 cell surface expression is a potential surrogate prognostic marker of CLL favourable outcome. Several alternatively spliced isoforms have been reported for CD150: the canonical transmembrane CD150 isoform (mCD150) with two ITSM signaling motifs in the cytoplasmic domain, a secreted CD150 isoform (sCD150) without a transmembrane region, and a novel CD150 isoform (nCD150) with an alternative cytoplasmic tail [ 19 , 20 ]. However, the profile of CD150 isoform expression in CLL has not been analysed.…”
Section: Introductionmentioning
confidence: 99%